G1 Therapeutics (GTHX)
(Real Time Quote from BATS)
$3.08 USD
-0.13 (-4.05%)
Updated Jun 6, 2024 10:20 AM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
G1 Therapeutics [GTHX]
Reports for Purchase
Showing records 141 - 160 ( 351 total )
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Cosela Growing Steadily in Q2, NTAP Should Fuel Q4.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
2Q21: COSELA Sales Improve Sequentially and Should Do so in Q3 and Q4.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
FDA Grants Fast Track Designation for Cosela in Combination With Chemo for Locally Advanced or mTNBC
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Continued Execution to Expand COSELA Beyond Lung Cancer
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Highlights From Non-Deal Roadshow With G1 Therapeutics
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
G1 Therapeutics Initiates the Phase 2 PRESERVE 3 Study of Cosela in Bladder Cancer
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Updated Data for Rintodestrant in Combination With Ibrance for ER+/HER2- Advanced Breast Cancer at ASCO 2021
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Update on Rintodestrant and Trilaciclib Presented at ASCO 2021
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Positive Rintodestrant Combination Data in ASCO Abstract
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Phase 2 PRESERVE 4 Study of Cosela in NSCLC Patients Previously Treated with Checkpoint Inhibitors Initiated
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E